Alkem Laboratories has announced that its board of directors will convene on February 13 to consider and approve the company's third quarter financial results. The pharmaceutical company's scheduled board meeting represents a key milestone in its quarterly financial reporting cycle.

Board Meeting Schedule

The upcoming board meeting details are outlined below:

Quarterly Results Process

The February 13 board meeting will focus on reviewing and approving the third quarter financial performance. This scheduled meeting follows standard corporate governance practices for publicly listed pharmaceutical companies, ensuring proper oversight and approval of financial disclosures before public release.

Market Expectations

Investors and market participants will be monitoring the outcome of this board meeting, as the approved Q3 results will provide insights into Alkem Laboratories' operational performance during the quarter. The company's financial metrics and business developments will be formally disclosed following the board's consideration and approval process.

The announcement of the board meeting date provides stakeholders with advance notice of when the Q3 financial results will be available for review and analysis.

Alkem laboratories has received a GST demand order from tax authorities, requiring the pharmaceutical company to pay ₹2.35 crores along with penalty and interest. The company disclosed this development to stock exchanges under Regulation 30 of SEBI listing regulations on January 22, 2026.

GST Demand Order Details

The order was issued by the Additional Commissioner, Central Goods & Services Tax, Goa, covering the assessment period from 2019-2020 to 2022-2023. The demand pertains to the company's Goa GSTIN operations during this four-year period.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit by the company during the specified period. The order has been issued under the applicable provisions of multiple GST legislations:

• IGST Act, 2017
• CGST Act, 2017
• SGST Act, 2017

The total financial implication includes the principal GST amount of ₹2.35 crores along with applicable interest and an equal penalty amount of ₹2.35 crores.

Company's Response and Legal Action

Alkem Laboratories has clearly stated its disagreement with the demand order and plans to contest the allegations. The company is preparing to take appropriate legal action, including filing an appeal against the order issued by the tax authorities.

The pharmaceutical company has emphasized that it does not agree with the findings in the demand order and will challenge the assessment through proper legal channels available under GST regulations.

Financial and Operational Impact

According to the company's disclosure, there is no material impact expected on its financial, operational, or other business activities from this GST demand order. This assessment suggests that the company views the order as contestable and expects to successfully challenge the allegations through the appeals process.

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, ensuring transparency with investors and stakeholders about this regulatory development.